Longeveron granted Canadian patent covering laromestrocel administration

Longeveron (LGVN) announced that the Canadian Intellectual Property Office has granted a patent covering administration of laromestrocel, the Company’s proprietary mesenchymal stem cells, for the treatment of patients with symptoms of aging-related frailty and also for the treatment of non-ischemic dilated cardiomyopathy. Canadian Patent No. 3043594, entitled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” provides Longeveron with patent rights in Canada through 2037.